Removal of DOACs from plasma:performance comparison and pre-analytical considerations of three different devices by Bouvy, Céline et al.
RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE
Author(s) - Auteur(s) :
Publication date - Date de publication :
Permanent link - Permalien :
Rights / License - Licence de droit d’auteur :
Bibliothèque Universitaire Moretus Plantin
Institutional Repository - Research Portal
Dépôt Institutionnel - Portail de la Recherche
researchportal.unamur.be
Removal of DOACs from plasma
Bouvy, Céline; Evrard, Jonathan; Siriez, Romain; Mullier, François; Douxfils, Jonathan;
Gheldof, Damien
Publication date:
2018
Document Version
Publisher's PDF, also known as Version of record
Link to publication
Citation for pulished version (HARVARD):
Bouvy, C, Evrard, J, Siriez, R, Mullier, F, Douxfils, J & Gheldof, D 2018, 'Removal of DOACs from plasma:
performance comparison and pre-analytical considerations of three different devices', European Congress on
Thrombosis and Haemostasis, Marseille, France, 24/10/18 - 26/10/18.
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 17. Jan. 2020
Introduction
Methods
Céline Bouvy1, Jonathan Evrard2, Romain Siriez2, François Mullier3, Jonathan Douxfils1,2, Damien Gheldof2
1QUALIblood sa, 2Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS),
University of Namur, Namur, Belgium 3Hematology laboratory, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences
(NARILIS), Université Catholique de Louvain, Yvoir, Belgium
Given the plethora of coagulation tests influenced by Direct Oral Anti-Coagulants (DOACs), it would be of particular interest to remove DOACs from a sample. This could
enable a better investigation of an underlying plasma defect potentially hidden by a DOAC interference. In this context, several DOACs-removal devices have been
developed for a potential use in clinical routine. The transfer of plasma through a filter or the addition of an adsorbing agent is currently under investigation.
The aim of this study was to evaluate the performances of three devices enabling the removal of DOACs from spiked plasma samples. Their efficiency to eliminate
DOACs from plasma, the impact of the transfer through the filters on the coagulation and their ergonomics were investigated.
Fresh normal pooled plasma from 6 healthy volunteers were mixed with either dabigatran, rivaroxaban or apixaban at 0-125-250-500 ng/mL theoretical final concentration.
Six hundred µL of plasma were tested before and after filtration on DOAC filter (Stago, France), DOAC Stop (Haematex Research, Australia) or on Hemofilter (Hemosafe,
Belgium) on a STA-R Max2 analyzer using calibrated STA-Liquid anti-Xa or STA-ECAII for dosage of anti-Xa and anti-IIa drugs, respectively (all products from Stago,
France). Prothrombin time (PT) and activated partial thromboplastin time (aPTT) were also analyzed on the STA-R Max2. Several usage data regarding these devices were
collected throughout the study.
We thank Stago for having kindly provide us with reagents and DOAC filters for this study. Dr. Céline Bouvy: celine.bouvy@qualiblood.euinfo@qualiblood.eu
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1- Procedure for DOAC removal
DOAC filter DOAC Stop Hemofilter
Centrifugation 
300g, 15 min 
Gentle mix 
5 min 
Centrifugation
200g, 3 min 
Centrifugation
2000g, 2 min 
Quick vortex 
and 5 min 
incubation
Supernatant
transfer
Total time for use
15 min 7 min 8 min
Plasma volume loss
100±13 µL 150 µL* 68±3 µL
*defined in the experimental design.
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2- DOAC removal efficiency
3- Impact on PT and aPTT
Dabigatran Rivaroxaban Apixaban
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Some discrepancies can be observed between theoretical and actual dosages of dabigatran, rivaroxaban and apixaban in
spiked samples. Results also show that all devices enable a sufficient removal of rivaroxaban and dabigatran to lower
measurements under the limits of detection of the instrument (LOD is presented as horizontal dotted line). For apixaban, only
the DOAC Stop and the Hemofilter enable this sufficient elimination while residual amounts of apixaban are still measurable
after the use of the DOAC filter on samples containing the highest concentrations tested (250 and 500 ng/mL theoretical).
All the DOACs-removal devices were able to restore normal PT and aPTT, but Hemofilter introduced a slight shortening of PT
under every condition while it has no impact on aPTT.
Regarding their ergonomics and usage data, the DOAC
Stop procedure is the quickest (7 min). However, the
complete elimination of the adsorbing agent is difficult and
black residues in the sample were still visible after the
procedure and may lead to inadvertent transfer of the
black residue which will re-introduce the DOAC into the
sample. The use of DOAC filter and Hemofilter include less
steps in their protocol. The Hemofilter induces the lower
loss of sample volume.
Conclusion
In conclusion, the DOAC Filter and the Hemofilter are the easiest DOAC removal devices to use. In addition, no visible residues potentially interfering with measurement are
observed with these devices as opposed to DOAC Stop. However, the DOAC Filter is not able to eliminate apixaban at concentration higher than 250 ng/mL.
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